Altimmune Shares Poised for Potential Breakthrough

Altimmune finds itself at a critical juncture this quarter, with its shares potentially on the verge of a significant move. The biopharmaceutical company, buoyed by stronger-than-anticipated quarterly results and promising clinical data for its drug candidate Pemvidutide, anticipates a pivotal year. The forthcoming 48-week data, expected before year’s end, is set to determine the company’s trajectory.

The immediate future for Altimmune is defined by two major upcoming events, both scheduled for this quarter. The release of the 48-week data from the IMPACT study is highly anticipated, alongside a scheduled FDA meeting to outline the Phase 3 clinical trial for Pemvidutide. These events represent significant catalysts that could validate the drug’s Read more...